Clara E. Gavira-O'Neill, Jie-Xian Dong, James S. Trimmer
下载PDF
{"title":"用于神经科学研究的骆驼源纳米体的开发、筛选和验证","authors":"Clara E. Gavira-O'Neill, Jie-Xian Dong, James S. Trimmer","doi":"10.1002/cpns.107","DOIUrl":null,"url":null,"abstract":"<p>Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.</p><p>This article was corrected on 26 June 2021. See the end of the full text for details.</p><p><b>Basic Protocol 1</b>: Total RNA isolation from camelid leukocytes</p><p><b>Basic Protocol 2</b>: First-strand cDNA synthesis; V<sub>H</sub>H and V<sub>H</sub> repertoire PCR</p><p><b>Basic Protocol 3</b>: Preparation of the phage display library</p><p><b>Basic Protocol 4</b>: Panning of the phage display library</p><p><b>Basic Protocol 5</b>: Small-scale nAb expression</p><p><b>Basic Protocol 6</b>: Sequence analysis of selected nAb clones</p><p><b>Basic Protocol 7</b>: Nanobody validation as immunolabels</p><p><b>Basic Protocol 8</b>: Generation of nAb-pEGFP mammalian expression constructs</p><p><b>Basic Protocol 9</b>: Nanobody validation as intrabodies</p><p><b>Support Protocol 1</b>: ELISA for llama serum testing, phage titer, and screening of selected clones</p><p><b>Support Protocol 2</b>: Amplification of helper phage stock</p><p><b>Support Protocol 3</b>: nAb expression in amber suppressor <i>E. coli</i> bacterial strains</p>","PeriodicalId":40016,"journal":{"name":"Current Protocols in Neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpns.107","citationCount":"3","resultStr":"{\"title\":\"Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research\",\"authors\":\"Clara E. Gavira-O'Neill, Jie-Xian Dong, James S. Trimmer\",\"doi\":\"10.1002/cpns.107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.</p><p>This article was corrected on 26 June 2021. See the end of the full text for details.</p><p><b>Basic Protocol 1</b>: Total RNA isolation from camelid leukocytes</p><p><b>Basic Protocol 2</b>: First-strand cDNA synthesis; V<sub>H</sub>H and V<sub>H</sub> repertoire PCR</p><p><b>Basic Protocol 3</b>: Preparation of the phage display library</p><p><b>Basic Protocol 4</b>: Panning of the phage display library</p><p><b>Basic Protocol 5</b>: Small-scale nAb expression</p><p><b>Basic Protocol 6</b>: Sequence analysis of selected nAb clones</p><p><b>Basic Protocol 7</b>: Nanobody validation as immunolabels</p><p><b>Basic Protocol 8</b>: Generation of nAb-pEGFP mammalian expression constructs</p><p><b>Basic Protocol 9</b>: Nanobody validation as intrabodies</p><p><b>Support Protocol 1</b>: ELISA for llama serum testing, phage titer, and screening of selected clones</p><p><b>Support Protocol 2</b>: Amplification of helper phage stock</p><p><b>Support Protocol 3</b>: nAb expression in amber suppressor <i>E. coli</i> bacterial strains</p>\",\"PeriodicalId\":40016,\"journal\":{\"name\":\"Current Protocols in Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/cpns.107\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Protocols in Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpns.107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpns.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 3
引用
批量引用
Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research
Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.
This article was corrected on 26 June 2021. See the end of the full text for details.
Basic Protocol 1 : Total RNA isolation from camelid leukocytes
Basic Protocol 2 : First-strand cDNA synthesis; VH H and VH repertoire PCR
Basic Protocol 3 : Preparation of the phage display library
Basic Protocol 4 : Panning of the phage display library
Basic Protocol 5 : Small-scale nAb expression
Basic Protocol 6 : Sequence analysis of selected nAb clones
Basic Protocol 7 : Nanobody validation as immunolabels
Basic Protocol 8 : Generation of nAb-pEGFP mammalian expression constructs
Basic Protocol 9 : Nanobody validation as intrabodies
Support Protocol 1 : ELISA for llama serum testing, phage titer, and screening of selected clones
Support Protocol 2 : Amplification of helper phage stock
Support Protocol 3 : nAb expression in amber suppressor E. coli bacterial strains
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
